Chronic pain is a major global health problem. The drugs that are currently used to treat the condition have limitations, such as side effects and insufficient pain relief. Therefore, research is underway to develop therapeutic antibodies that can target pain receptors. One receptor that has been of great interest for its involvement in chronic pain is transient receptor potential vanilloid 1 (TRPV1). The project investigated whether two antibodies, antibody A and B, could bind to TRPV1 and affect its function in vitro. This was done to determine whether the antibodies could be potential drug candidates for the treatment of chronic pain. The conclusion of the project is that antibody B could potentially be an effective treatment for chronic pain and is thus suitable for further research.